阿茲海默症診斷和治療市場：按產品和地區分類的市場規模、佔有率、前景和機會分析（2025-2032 年）

Alzheimers disease diagnostics and therapeutics Market, by Product, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，阿茲海默症診斷和治療市場規模將達到 77.045 億美元，到 2033 年將達到 112.821 億美元。預計從 2026 年到 2033 年，該市場將以 5.6% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	77.045億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	5.60%	2033年市場規模預測：	112.821億美元

阿茲海默症是神經退化性疾病，通常進展緩慢且逐漸惡化。它是一種進行性失智症，其特徵是認知能力、行為和社交技能持續下降，最終損害患者的獨立生活能力。醫生會進行一系列檢查以排除其他可能導致功能障礙的原因。目前有多種診斷方法。 CT 和 MRI 等成像技術主要用於排除其他與阿茲海默症症狀相似但治療方法根治性的疾病。阿茲海默症目前尚無治癒方法，但有一些治療方案可以延緩疾病進展，藥物和非藥物療法可以幫助緩解症狀。阿杜卡奴單抗是目前唯一獲準用於治療阿茲海默症的緩解疾病藥物。藥物治療可以暫時改善症狀或延緩疾病進展。這些治療方法可以幫助阿茲海默症症患者在一段時間內保持最佳功能和獨立生活能力。在疾病的晚期，與嚴重腦功能障礙相關的併發症（脫水、營養不良、感染疾病等）成為死亡原因。

市場動態

隨著生物標記在阿茲海默症診斷和藥物研發中應用日益廣泛，以及為應對日益沉重的疾病負擔而對新型診斷和治療方法研發的日益重視，預計全球阿茲海默症診斷和治療市場將持續成長。例如，2021年6月，阿茲海默症基金會（ADDF）的診斷加速器啟動了四項新的研究投資，用於開發阿茲海默症診斷的數位食品藥物管理局。此外，2022年8月，阿茲海默症協會宣布推出阿茲海默症治療和診斷網路（ALZ-NET）。該平台旨在收集在真實臨床環境中接受FDA批准的阿茲海默症治療的患者的長期臨床和安全性數據。這是第一個專門為獲得 FDA 批准的阿茲海默症治療藥物而建立的網路，它將長期收集有關藥物療效和副作用的真實世界證據。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數，對全球阿茲海默症診斷和治療市場的主要公司進行了概況介紹：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份《全球阿茲海默症診斷與治療市場》報告的目標對象包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
相關人員可以透過利用全球阿茲海默症診斷和治療市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第6章競爭情勢

Luye Pharma Group
Vigil Neuroscience, Inc.
Grifols, SA
AbbVie Inc.
Zydus Lifesciences Ltd.
Merck KGaA
F. Hoffmann-La Roche Ltd.
Novartis AG
Johnson & Johnson
Eli Lilly and Company
Biogen Inc.
Siemens Healthcare GmbH
Merz Pharma
Eisai Co. Ltd.
Lupin Limited
Teva Pharmaceutical Industries Ltd.
Apotex Inc.
Corium, Inc.
Supernus Pharmaceuticals, Inc.

第7章

調查方法
關於本公司

簡介目錄

Product Code: CMI5181

Alzheimer's Disease Diagnostics and Therapeutics Market is estimated to be valued at USD 7,704.5 Mn in 2026 and is expected to reach USD 11,282.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7,704.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.60%	2033 Value Projection:	USD 11,282.1 Mn

Alzheimer's disease is a neurodegenerative disease that usually starts slowly and progressively worsens. It is a progressive form of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. Doctors perform a series of tests to rule out other possible causes of impairment. It can be diagnosed in several different ways. Imaging techniques, such as CT and MRI, are primarily used to rule out other conditions that may cause symptoms similar to Alzheimer's but require different treatment. There's no cure for Alzheimer's disease, but there are treatments that may change disease progression, and drug and non-drug options that may help treat symptoms. Aducanumab is the only disease-modifying medication currently approved to treat Alzheimer's. Medications may temporarily improve or slow progression of symptoms. These treatments can sometimes help people with Alzheimer's disease maximize function and maintain independence for a time. In advanced stages of the disease, complications from severe loss of brain function - such as dehydration, malnutrition or infection - result in death.

Market Dynamics

Increasing use of biomarkers in Alzheimer's diagnosis and drug development and increasing focus on the development of novel diagnostics & therapeutics due to increase in disease burden is expected to boost the growth of the global Alzheimer's disease diagnostics and therapeutics market. For instance, in June 2021, the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator launched four new research investments for the development of digital biomarkers for Alzheimer's diagnosis. Moreover, in August 2022, the Alzheimer's Association announced the launch of Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), a platform to collect long-term clinical and safety data from patients treated with U.S FDA-approved Alzheimer's disease therapies in real world clinical settings. It is the first network developed specifically for FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Alzheimer's disease diagnostics and therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Alzheimer's disease diagnostics and therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alzheimer's disease diagnostics and therapeutics market

Detailed Segmentation:

Global Alzheimer's Disease Diagnostics And Therapeutics Market, By Product (Revenue, USD Mn, 2021 - 2033)
Therapeutics
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Others
Diagnostics
- Brain Imaging
- CSF Test for Alzheimer's Disease
Global Alzheimer's Disease Diagnostics And Therapeutics Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Region/Country
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Luye Pharma Group
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Vigil Neuroscience, Inc.
Grifols, S.A.
AbbVie Inc.
Zydus Lifesciences Ltd.
Merck KGaA
Hoffmann-La Roche Ltd.
Novartis AG
Johnson & Johnson
Eli Lilly and Company
Biogen Inc.
Siemens Healthcare GmbH
Merz Pharma
Eisai Co. Ltd.
Lupin Limited
Teva Pharmaceutical Industries Ltd.
Apotex Inc.
Corium, Inc.
Supernus Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pipeline Analysis
PEST Analysis

4. Global Alzheimer's Disease Diagnostics and Therapeutics Market, By Product, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Therapeutics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  - Cholinesterase Inhibitors
  - NMDA Receptor Antagonists
  - Others
Diagnostics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
  - Brain Imaging
  - CSF Test for Alzheimer's Disease

5. Global Alzheimer's Disease Diagnostics and Therapeutics Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

6. Competitive Landscape

Luye Pharma Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Vigil Neuroscience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Grifols, S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Zydus Lifesciences Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Siemens Healthcare GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merz Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eisai Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Corium, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Supernus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies